Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide gel - Double Bond Pharmaceutical

Next Previous
Drug Profile

Temozolomide gel - Double Bond Pharmaceutical

Alternative Names: SI 053; Temodex

Latest Information Update: 19 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Research Institute for Physical Chemical Problems of the Belarusian State University
  • Developer Double Bond Pharmaceutical; RUE Belmedpreparaty
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioblastoma

Most Recent Events

  • 10 Mar 2025 Double Bond Pharmaceutical International and Vivo Biopharma extends the Asset Purchase and Collaboration Agreements for SI-053, and related assets
  • 10 Mar 2025 Double Bond Pharmaceutical receives the Competent Authority and Ethics Committee approvals to initiate a phase I clinical trial in two western European countries
  • 12 Sep 2024 Temozolomide gel is still in preclinical development in Glioblastoma in Sweden (Intracerebral, Gel) (Double Bond Pharmaceuticals pipeline, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top